Khiron continues to support T21 with affordable options

Sponsored content

Khiron Life Sciences is continuing to support Project T21 with affordable options, which allow for more comprehensive treatment of chronic conditions.

Earlier this year Drug Science announced key changes to its medical cannabis registry, now known as T21, as it continues into its fourth year.

The subsidised pricing structure has changed to a new model, in which the cost of treatment is determined by each producer who partners with T21, not by Drug Science. 

Registered patients will now receive a minimum of 5% discount on all cannabis-based medicinal products (CBMPs) included in the T21 formulary.

Khiron Life Sciences has announced today that it has temporarily added additional products into the lowest tier of pricing, to ensure that patients have access to a comprehensive list of options that can cover all of the prescriber’s needs at affordable prices.

Franziska Katterbach, president of Khiron Europe, commented: “As a continued effort to support the T21 project, and an ad-hoc measure for patients, we wanted to be cost-minded and expand our offering to further support the project.

“Patients are at the heart of what we do, we feel by adding additional products at £5 per gram would give patients further choice and more comprehensive, affordable treatment options.”

The idea of mixing and matching chemotypes to find the appropriate level of therapeutic results has long been supported by the company’s global scientific director, Dr Guillermo Moreno Sanz. You can read more in his Finding the right balance article.

Dr Moreno Sanz said: “We are cognisant chemotype 1 flos (THC-predominant) are the most prescribed CBMPs in T21. For this reason, we decided to offer a good daytime complement to our T21 flagship cannabis flower, so that patients have a choice of irradiated and non-irradiated CBMPs at affordable prices.

“However, we would like to see UK patients and prescribers considering also balanced flowers, which are a very popular option in more mature medicinal markets such as Germany and Canada and may help patients gradually reduce THC consumption over time.“

Khiron Life Sciences has been committed to T21 since its inception, with a focus on leveraging the data collected by the patient registry over the past three years to generate real-world evidence that supports the access to medical cannabis in the UK. The team continues to investigate the safety and efficacy of medical cannabis in treating novel conditions, to ultimately reach the goal of bringing cannabis into the mainstream healthcare system, including through NHS prescriptions.

• UK patient registry to continue for fourth year with key changes
• Finding the right balance: the benefits of mixing THC and CBD flower
• Nine out of 10 chronic pain patients see improvements with cannabis
• Khiron’s medical cannabis training gains UK CPD approval
• Study suggests Gb Sciences’ cannabinoid mixtures could treat Parkinson’s